[ad_1] Biogen has reached a deal to buy Alcyone Therapeutics, a privately held company that has developed a system for delivering antisense oligonucleotides (ASOs) directly into the central nervous system. The deal – which includes an upfront payment of $85 million – could accelerate Biogen’s efforts to develop a new formulation of its antisense therapeutic…
[ad_1] Eisai and Biogen have won FDA approval for a subcutaneous injection version of Leqembi that could help accelerate uptake of the Alzheimer’s disease therapy. The green light for Leqembi Iqlik (lecanemab) means it can be used as an alternative to infusions during the maintenance phase of treatment with the anti-amyloid therapy, and patients will…
[ad_1] Biogen, Eisai get USFDA nod for Leqembi Iqlik Subcutaneous Injection for maintenance dosing for early Alzheimer’s Disease We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen’s much-delayed drug for early-stage Alzheimer’s disease. Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday (1st September), becoming the first drug in the class to…